To identify the drug candidates, researchers studied the genes of the novel coronavirus and how it infects human cells. The study was published on bioRxiv, a website for preprinted biology studies, and the researchers have submitted it to a journal for publication.
The researchers identified 69 drug candidates, 24 of which already are FDA-approved to treat other diseases such as cancer, Parkinson’s disease and hypertension.
Other drug candidates on the list include haloperidol, used to treat schizophrenia, and metformin, used by patients to help manage Type 2 diabetes.
The list also includes drug candidates that are in clinical trials, antibiotics that kill bacteria by targeting how they build proteins, and chloroquine, an antimalarial drug.
Chloroquine has received a lot of attention since last week, when President Donald Trump called the drug a “game changer” for COVID-19 at a news briefing at the White House.
Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, added a warning that there was only “anecdotal evidence” that chloroquine could help treat COVID-19, according to the report.
View the full list of 69 drug candidates, compounds here.
More articles on pharmacy:
CVS clarifies policies after 4,000+ workers petition for sick pay, protective gear
WHO launches clinical trial in 10 countries to find COVID-19 treatment
How top retail pharmacy chains have responded to the coronavirus pandemic
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
